|
Aug 30
|
BioSyent (CVE:RX) Has Announced A Dividend Of CA$0.045
|
|
Aug 28
|
BioSyent Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS In Line
|
|
Aug 26
|
BioSyent Releases Financial Results for Q2 and H1 2024
|
|
Aug 26
|
BioSyent Declares Third Quarter 2024 Dividend
|
|
Jul 24
|
FAX Capital Files Early Warning Report Regarding Disposition of Common Shares of BioSyent Inc.
|
|
Jun 12
|
BioSyent In-Licenses Endocrinology Product for Canada
|
|
May 10
|
Increases to CEO Compensation Might Be Put On Hold For Now at BioSyent Inc. (CVE:RX)
|
|
May 9
|
BioSyent Schedules Q1 2024 Earnings Release for May 16, 2024
|
|
Apr 3
|
FeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians for Ninth Consecutive Year
|
|
Mar 27
|
BioSyent Announces Grant of Restricted Share Units
|
|
Mar 6
|
BioSyent Schedules Fourth Quarter and Full Year 2023 Earnings Release for March 13, 2024
|
|
Feb 6
|
BioSyent Declares First Quarter 2024 Dividend
|
|
Aug 8
|
BioSyent Launches Inofolic® for Women with Polycystic Ovary Syndrome (PCOS)
|